spacer
home > ebr > summer 2018 > the patent dance
PUBLICATIONS
European Biopharmaceutical Review

The Patent Dance

The state of biosimilars in the US has never been hotter; 2017 was the most active year to date for biosimilar drug manufacturers since the Biologics Price Competition and Innovation Act (BPCIA) was enacted by Congress. Recent decisions by the Supreme Court of the US and the US Court of Appeals for the Federal Circuit have indelibly altered the landscape of biosimilar litigation. Now, biosimilar applicants can eliminate the nearly eight-month information exchange process and/or collapse the two litigation phases into one single action − effectively expediting the litigation and potentially accelerating market entry.

Rounds of Disclosure

Enacted in 2010, the BPCIA created an abbreviated approval pathway for biosimilars (1). The BPCIA facilitates litigation during the period preceding FDA approval of the biosimilar so that the parties may attempt to resolve their patent disputes prior to commercial marketing (2). However, several key differences exist. Besides the absence of an Orange Book for patents covering biological products, the most notable distinction between the BPCIA and Hatch-Waxman schemes is how patent litigation can impact the approval and launch of a follow-on biologic. As set forth in 42 USC § 262 (l), a ‘patent dance’ is contemplated, consisting of several ‘rounds’ of disclosure and information exchange.

The first round of this dance starts rapidly. Within 20 days of the FDA’s acceptance of an Abbreviated Biologics License Application (aBLA), the BPCIA contemplates that a biosimilar applicant provides the reference product sponsor confidential access to its full aBLA application (2). Furthermore, the biosimilar applicant can provide the reference product sponsor detailed information concerning the biosimilar product’s manufacturing process (2). Sixty days after this initial exchange, the reference product sponsor must provide the biosimilar applicant with a list of unexpired patents for which a claim of infringement could reasonably be made, as well as any licensing offers (2). The biosimilar applicant then has another 60 days to provide detailed invalidity, unenforceability, and/or noninfringement contentions for each of the asserted patents (2). What follows next is an additional series of responses, culminating over an eight-month period, with the innovator bringing suit in a US federal court. However, if the biosimilar applicant fails to engage in this disclosure process, the reference product sponsor may file an immediate declaratory judgment action on any of those unexpired patents that could be reasonably asserted.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sanya Sukduang is a partner at Finnegan, Henderson, Farabow, Garrett & Dunner. He has a dynamic practice litigating matters concerning abbreviated new drug application challenges for brand drug manufacturers, diagnostic methods, biological products, and medical devices. Sanya has been the recipient of various awards and nominations, including Best Lawyers Under 40 by the National Asian Pacific American Bar Association.

Thomas J Sullivan is an associate at Finnegan. His practice focuses on complex patent litigation related to the pharmaceutical and biotechnology fields. He is actively involved in Hatch-Waxman litigation proceedings at the district court level and in appeals to the Federal Circuit.
spacer
Sanya Sukduang
spacer
spacer
spacer
Thomas J Sullivan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TLX Cargo and EMBALL ISO agree a partnership that allows pharmaceutical companies and airlines to have a single point of contact for the thermal protection of their shipments

St Georges de Reneins, January 28th 2019 _ TLX Cargo, part of TLX insulation Ltd, world leading manufacturer of thin reflective insulation for 25 years, offer its Thermal blankets through EMBALL’ISO worldwide commercial network.
More info >>

White Papers

Autoinjector testing made safe efficient and flexible

ZwickRoell

The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement